Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 6, 2013, Pages 392-400

  Cars, Thomas ^a,b   Wettermark, Björn ^a,c,d   Malmström, Rickard E ^d   Ekeving, Gunnar ^d   Vikström, Bo ^d   Bergman, Ulf ^c,d   Neovius, Martin ^c   Ringertz, Bo ^d   Gustafsson, Lars L ^d  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ARTICLE; AUTOMATIC DATA EXTRACTION; AUTOMATION; COMPUTER PROGRAM; COMPUTER SYSTEM; CONTROLLED STUDY; DATA EXTRACTION; ELECTRONIC MEDICAL RECORD; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL INFORMATION SYSTEM; HUMAN; ICD-10; INTERMETHOD COMPARISON; MODEL; PRESCRIPTION; PRIORITY JOURNAL; SEMI AUTOMATIC DATA EXTRACTION; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG UTILIZATION; ELECTRONIC HEALTH RECORDS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL RECORD LINKAGE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84878123831     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12055     Document Type: Article

References (35)

1. Grapow MT, von Wattenwyl R, Guller U, Beyersdorf F, Zerkowski HR. Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines!. The Journal of thoracic and cardiovascular surgery 2006;132:5-7.
2. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discovery 2011;10:495-506.
3. Avorn J, Fischer M. 'Bench to behavior': translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood). 2010;29:1891-900.
4. Larsson S, Lawyer P, Garellick G, Lindahl B, Lundstrom M. Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value. Health Aff (Millwood). 2012;31:220-7.
5. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-37.
6. Larsen MD, Cars T, Hallas J. A MiniReview of the Use of Hospital-based Databases in Observational Inpatient Studies of Drugs. Basic Clin Pharmacol Toxicol 2013;112:13-8.
7. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
8. Hennessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:311-3.
9. Mohamed IN, Helms PJ, McLay JS. Using primary care prescribing databases to determine drug switching and continuation of care. Basic Clin Pharmacol Toxicol 2012;111:396-401.
10. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
11. EurapStudyGroup. Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. Epilepsia. 2009;50:2305-9.
12. Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009;218:347-56.
13. Fayyad U, Piatetsky-Shapiro G, Smyth P. From Data Mining to Knowledge Discovery in Databases. American Association for Artificial Intelligence. 1996;17:37-54.
14. Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008;22:127-40.
15. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004;57:127-34.
16. Dean BB, Lam J, Natoli JL, Butler Q, Aguilar D, Nordyke RJ. Review: use of electronic medical records for health outcomes research: a literature review. Medical care research and review: MCRR. 2009;66:611-38.
17. Haerian K, Varn D, Vaidya S, Ena L, Chase HS, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther 2012;92:228-34.
18. Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. Eur J Clin Pharmacol 2013;69:255-9.
19. Yoon D, Park MY, Choi NK, Park BJ, Kim JH, Park RW. Detection of Adverse Drug Reaction Signals Using an Electronic Health Records Database: comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) Algorithm. Clin Pharmacol Ther 2012;91:467-74.
20. Park MY, Yoon D, Lee K, Kang SY, Park I, Lee SH et al. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database. Pharmacoepidemiol Drug Saf 2011;20:598-607.
21. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010;46:395-404.
22. Zhang Q, Matsumura Y, Teratani T, Yoshimoto S, Mineno T, Nakagawa K et al. The application of an institutional clinical data warehouse to the assessment of adverse drug reactions (ADRs). Evaluation of aminoglycoside and cephalosporin associated nephrotoxicity. Methods Inf Med 2007;46:516-22.
23. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert review of pharmacoeconomics & outcomes research. 2009;9:65-83.
24. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
25. Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC health services research. 2010;10:128.
26. Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011;40:8-15.
27. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
28. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158, iii-iv.
29. Woolacott N, Bravo VergelY, Hawkins N, Kainth A, Khadjesari Z, Misso K et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii-iv, xiii-xvi, 1-239.
30. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7:1-67.
31. Arnold FW, McDonald LC, Smith RS, Newman D, Ramirez JA. Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2006;27:378-82.
32. Carlhed R, Bojestig M, Wallentin L, Lindstrom G, Peterson A, Aberg C et al. Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J 2006;152:1175-81.
33. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE 2012;7.
34. Gustafsson LL, Wettermark B, Kalin M, Korkmaz S, Persson ME, Almkvist H et al. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment}. Lakartidningen 2008;105:2917-22, [In Swedish]
35. Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J et al. The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33.